Apolipoprotein C-III

From Citizendium
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In medicine and physiology, apolipoprotein C-III is apolipoprotein that is "a 9-kDa protein component of very-low-density lipoproteins and chylomicron remnants. Apo C-III, synthesized in the liver, is an inhibitor of lipoprotein lipase. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (receptors, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of sialic acid (Apo C-III-0, Apo C-III-1, and Apo C-III-2)."[1]

Fatty liver and steatohepatitis may be caused by the single-nucleotide polymorphisms rs2854116 (c.455T>C) and rs2854117 (c.482C>T) of apolipoprotein C-III which are also associated with insulin resistance and hypertriglyceridemia.[2]

External links

References

  1. Anonymous (2024), Apolipoprotein C-III (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM et al. (2010). "Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease.". N Engl J Med 362 (12): 1082-9. DOI:10.1056/NEJMoa0907295. PMID 20335584. Research Blogging.